Paclitaxel onkovis

DRUG3 trials

Sponsors

Swiss Group for Clinical Cancer Research, NSABP Foundation Inc., Rheinische Friedrich-Wilhelms-Universitaet Bonn

Conditions

N2)Patients with early breast cancerResectablelocally advanced non-small cell lung cancer (NSCLCresectable and borderline resectable stage IIIA/B NSCLC

Phase 2

Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III(N2) non-small cell lung cancer (NSCLC). A multicenter phase II trial.

Active, not recruitingCTIS2023-504536-18-00

Swiss Group for Clinical Cancer Researchlocally advanced non-small cell lung cancer (NSCLC, N2), Resectable

Start: 2024-07-31Target: 10Updated: 2025-10-22

Prospective randomized Phase II trial on Induction Immunochemotherapy followed by surgery or definitive chemoradiation and consolidation Durvalumab (MEDI4736) in resectable and borderline resectable stage IIIA/B NSCLC

RecruitingCTIS2024-516367-80-00

Rheinische Friedrich-Wilhelms-Universitaet Bonnresectable and borderline resectable stage IIIA/B NSCLC

Start: 2025-04-24Target: 176Updated: 2025-10-10

Phase 3

A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo "GeparDouze"

CompletedCTIS2023-508472-11-00

NSABP Foundation Inc.Patients with early breast cancer

Start: 2018-06-13End: 2025-11-19Target: 978Updated: 2025-08-05